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The effects of dapiprazole on cyclopentolate 
Abstract 
Pupillary dilation to perform binocular indirect ophthalmoscopy and gain three dimensional evaluation of 
the disc, cup and macula is a routine part of optometric practice. However, many patients find the 
resulting photophobia and loss of near vision to be an inconvenience. Therefore, clinical interest in 
ophthalmic agents that will safely reverse the pharmacologically induced mydriasis and cycloplegia have 
existed for over fifty years. 0.5% dapiprazole HCL is a relatively new adrenergic agent reported to reverse 
the effects of pupillary dilation and cycloplegia secondary to tropicamide, phenylephrine hydrochloride 
and other analogs.2 To date, there have been no studies published to show the effects of dapiprazole on 
cyclopentolate, another popular cycloplegic/mydriatic agent. In this study, the clinical usefulness and 
efficacy of dapiprazole in reversing the effects of cyclopentolate were studied. A placebo in a masked 
(single blind) study was used. Bilateral cycloplegia was used to eliminate any residual accommodation 
that might have existed between the two eyes. Twenty seven subjects were tested: nine were used as 
controls, and eighteen were used as experimentals. The experimental group received two drops of 
dapiprazole administered five minutes apart in each eye 30 minutes after instillation of the cycloplegic 
drops. The control group received two drops of ocular lubricant administered five minutes apart. The 
diagnostic agents used for the experimental group were one drop each of 0.5% proparacaine and 1% 
cyclopentolate. Pupil diameter, amplitude of accommodation, and intraocular pressure were evaluated on 
each patient. These measurements were taken: (1) before instillation of the cycloplegic agents; (2) prior 
to instillation of dapiprazole (1 hour after cycloplegia); and (3) at 30, 60, 120, and 180 minutes after the 
final instillation of dapiprazole. Results indicated no significant difference on positive relative 
accommodation or negative relative accommodation, or pupil diameter, but with a statistically significant 
difference in the other variable: decreased lOP. Suggestive trends to dapiprazole's effects on 
cyclopentolate do exist that could be turned into statistical trends with an increase in number of test 
subjects and thier ages. 
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Abstract-
Pupillary dilation to perform binocular indirect ophthalmoscopy and gain 
three dimensional evaluation of the disc, cup and macula is a routine part of 
optometric practice. However, many patients find the resulting photophobia and 
loss of near vision to be an inconvenience. Therefore, clinical interest in 
ophthalmic agents that will safely reverse the pharmacologically induced 
mydriasis and cycloplegia have existed for over fifty years. 
0.5% dapiprazole HCL is a relatively new adrenergic agent reported to 
reverse the effects of pupillary dilation and cycloplegia secondary to 
tropicamide, phenylephrine hydrochloride and other analogs.2 To date, there 
have been no studies published to show the effects of dapiprazole on 
cyclopentolate, another popular cycloplegic/mydriatic agent. 
In this study, the clinical usefulness and efficacy of dapiprazole in 
reversing the effects of cyclopentolate were studied. A placebo in a masked 
(single blind) study was used. Bilateral cycloplegia was used to eliminate any 
residual accommodation that might have existed between the two eyes. 
Twenty seven subjects were tested: nine were used as controls, and eighteen 
were used as experimentals. The experimental group received two drops of 
dapiprazole administered five minutes apart in each eye 30 minutes after 
instillation of the cycloplegic drops. The control group received two drops of 
ocular lubricant administered five minutes apart. The diagnostic agents used for 
the experimental group were one drop each of 0.5% proparacaine and 1% 
cyclopentolate. 
Pupil diameter, amplitude of accommodation, and intraocular pressure 
were evaluated on each patient. These measurements were taken: (1) before 
instillation of the cycloplegic agents; (2) prior to instillation of dapiprazole (1 
hour after cycloplegia); and (3) at 30, 60, 120, and 180 minutes after the final 
instillation of dapiprazole. 
Results indicated no significant difference on positive relative 
accommodation or negative relative accommodation, or pupil diameter, but with 
a statistically significant difference in the other variable: decreased lOP. 
Suggestive trends to dapiprazole's effects on cyclopentolate do exist tha~ could be 
turned into statistical trends with an increase in number of test subjects and thier 
ages. 
Introduction-
"No way, Doc! I have to be able to see in a couple of hours!" This is a 
common response to dilation and/or cycloplegia in these days of on-the-go living. 
Fortunately, dapiprazole has emerged and offers to the patient the option of a 
more rapid recovery from such aforementioned procedures. 
To date, numerous studies have been undertaken to illustrate the reversal 
effects of dapiprazole9 and associated reactions with tropicamide 1 ,2,3 ,4, 
phenylephrine5,6 and hydroxyamphetamine 7 ,8. Since cyclopentolate is a 
cholinergic receptor inhibitor and dapiprazole is an alpha receptor blocking 
agent, one would believe that dapiprazole should have no effect on cyclopentolate. 
No studies could be found to describe the effects of dapiprazole upon reversing 
the action of cyclopentolate. The purpose of this study is to determine if an 
interaction does exist. 
For this study it was hypothesized that, dapiprazole will have an effect 
upon cyclopentolate by enhancing the recovery period of cyclopentolate-induced 
cycloplegia, and that there would be a statistical difference showing definitive 
differences in accommodative abilities in the experimental and control groups. It 
was also hypothesized that during the pretest and the immediate 1-hour post-
cycloplegic periods no statistical difference in accommodation ability would exist 
for either the control or the experimental groups. 
Methods-
Twenty-seven subjects, ranging in age from six to twenty-eight years, were 
used for this study. The mean age of the subjects (19 male and 8 females) was ten 
years. A prudent case history was taken to confirm the absence of systemic or 
ocular disease. Only subjects meeting the following criteria were included in the 
study: spherical corrections of +3.00 diopters to -6.00 diopters of correction and 
less than one diopter of anisometropia between the two eyes. In order to be 
included in the study, the subjects could not have used any medication other than 
oral contraceptives in the preceding two week period. Pregnant women were 
excluded from the study. Each subject signed a waiver of informed consent 
before beginning the study. 
The initial examination included a refinement of auto refraction and an 
external ocular health examination. Optometric Extension Program norms were 
used for comparison to confirm that each subject had normal accommodative 
range for his/her age. 
The refinement of the refraction included a reading from an Allergen 
Humphrey auto refractor as well as a refinement of both the sphere and cylinder 
at distance. 
Also, each subject was matched against OEP norms to verify that the 
iris appearance, pupil reactivity and visual acuity were within norms for his/her 
age. Pupil reactivity was checked by using a penlight test for direct and 
consenual response, including ruling out a Marcus Gunn pupil. Visual acuity was 
measured by using a 20 foot lane and having the subject read the lowest line 
possible, first monocular and then binocular. 
A biomicroscopic exam was also performed to evaluate the external ocular 
health of the eye. 
Accommodation was evaluated binocularly by measuring both the positive 
relative accommdation and the negative relative accommodation at near using the 
20/20 line. The Donders card was also used as a second measure of positive 
relative accommodation. The Donders card was held at 40cm and the patient was 
asked to read the 0.62m print. The card was pushed towards the patient until 
he/she reached a point where he/she could no longer read it binocularly. 
Throughout the study, the pupil diameter was measured via a Burton lamp 
and a hand held pupillometer. Pupils were measured in the dark to avoid 
pupillary constriction. 
Intraocular pressures were obtained with an AO non-contact tonometer 
rather than with a Goldman tonometer because the repeated use of the applanation 
probe could cause an abrasion to the cornea that would affect vision. 
An artificial pupil was created by drilling a three millimeter diameter hole 
in an occluder. The artificial pupil provided a standard so that depth of focus 
remained constant throughout testing. The use of the three mm diameter 
artificial pupil was validated by both the study conducted by Nyman and Reich2 
and also the Southall study.2 Both studies show that a three mm pupil does not 
affect the depth of field any more than a three and a half mm aperture. Also 
Nyman and Reich's study showed that the cornea has better clarity within the 
central three mm area. Therefore, in this study, a three millimeter aperture was 
the control for the entrance to the pupil of the eye and when placed in the 
spectacle plane, provids a constant range of accommodation. According to 
Nyman and Reich, any larger artificial pupil may affect the accommodation.2 
Accommodation was measured both under monocular and binocular 
conditions with the best correction in place in the phoropter. The artificial pupil 
was placed behind the phoropter to insure that proper distance and measurements 
remained constant. Illumination used was equal to approximately 30 foot candles. 
A Danders card was then placed at 40 em and each subject was asked to the read 
the 0.62m line. The card was then pushed toward the subject until he/she first 
noticed an inability to read the line. A 20/20 line was then placed at 40cm where 
a blur out and a recovery were completed on both the negative and positive 
relative accommodation. This test was then immediately repeated a second time, 
and the average was recorded. 
Once the baseline measurements of pupil size, intraocular pressures and 
acconunodation were taken, one drop of proparcaine 0.5% was instilled in each 
eye with punctal occlusion. Two minutes later, one drop of cyclopentolate 1.0% 
was instilled in each eye. One hour later, after the cyclopentolate was instilled, 
intraocular pressures, pupil size, and accommodation were measured again. 
After these measurem~nts were taken, the subjects were randomly divided 
into two groups. Each subject in Group A received a drop of proparacaine 0.5% 
followed the placebo consisting of artificial ocular lubricant. This placebo was 
used to obtain a standard by creating a design that was single masked, i.e. only the 
examiners were informed about which drugs were used. Five minutes later, 
another drop of ocular lubricant was instilled. 
The subjects in Group B also received another drop of proparacaine 0.5% 
followed by one drop of dapriprazole 0.5% in each eye. Five minutes later, 
another drop of dapriprazole 0.5% was instilled. 
The subjects in both groups were observed every hour for three hours. 
Pupil size, intraocular pressures and accommodation were measured at each of 
these observation times. Throughout the study, examiners noted any adverse side 
effects from the medications, either objectively or subjectively. Any adverse 
effects were photographed with the Canon fundus camera (CR-45UAF). 
180 minutes after instillation of the first drop of dapiprazole, subjects were 
instructed to be aware of any side effects that may occur. Each subject received a 
pair of mydriatic glasses upon completion of the study to minimize glare. 
Results-
The initial results support the hypothesis that dapiprazole does aid in enhancing 
accommodative ability and reversing those effects induced by cyclopentolate. 
Comparison of the data in this study utilized the unpaired t-tail statistical 
analysis to show the difference or indifference between the control (placebo) 
group of eight subjects and the experimental (dapiprazole) group of seventeen 
subjects. For the pretest and the one-hour post-cycloplegic periods, two tail 
analysis was employed. This was done to determine if any deviation in any 
direction could be seen before dapiprazole was utilized. For this initial period, no 
difference was observed which was significant to p>0.05 (Table 1). 
I Table 1 I 
Unpaired t-Test X1: type (PRA) Y1: Pre-cyclo 
DF: Unpaired t Value Prob. (2-tail) 
23 I o.69n I 0.4927 
Count Mean: Std . Dcv.: Std. Err. : 
17 4.5935 2.6419 0.6408 
8 3.91 1.1085 0.3919 
Unpaired t-Test X1: type (PRA) Y2: 1 hr. cyclo 
DF: 
23 
Group: Count: Mean: Std. Dcv.: Std. Err. : 
E 17 -1.3153 1.2887 0.3126 
c 8 -1.04 1.7821 0.6301 
The data depicted in Table 1 showed that both the control group and the 
experimental group were statistically indifferent prior to the actual dapiprazole 
testing period. 
Data from the one, two and three hour post dapiprazole testing periods, 
was analyzed by the one tail "t" test. These results also showed that no statistical 
difference was observed (p>0.05) between. the control and experimental groups in 
dapiprazole's effect upon positive relative accommodation in the reversal of 
cyclopentolate (Table 2) 
(Table 2j 
Unpaired t-Test X1: type (PRA) Y3 : 1 hr. Dap 
DF: Unpaired t Value Prob. (1-tail) 
23 1 1.5433 1 .o682 
Count: Mean: Std. Dcv.: Std. Err.: 
17 -0.7565 2.2064 .5351 
8 -2.08 1.4121 .4992 
Unpaired t-Test X1: type (PRA) Y4: 2 hr. Dap 
DF: Un aired L Value Prob. 0-tail 
23 1.5459 .0679 
Group: Count: Mean:· Std. Dcv.: Std. Err.: 
E 17 +0.29 1.9919 .4831 
c 8 -1.72 1.1997 .4242 
Unpaired t-Test X1: type (PRA) Y5: 3 hr. Dap 
DF: Un aired t Value Proh. (1-tail 
23 1.4853 .0755 
Group: Count: Mean: Std. Dcv.: Std. Err.: 
E 17 1.085 2.3243 .5637 
c -1.38 3.3986 1.2016 
The difference was close to being significant (p-0.06) and there does appears to 
be a difference graphically (Graph 1 ). 
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At one-hour post-cycloplegia and one-hour after dapiprazole instillation, a 
significant difference (p=0.0015) was noted between the control and experimental 
groups in negative relative accommodation. Another interesting finding is the 
largely significant difference (p=0.0282->p=0.0031). found in intraocular 
pressure in the two and three-hour post dapiprazole findings with no significant 
difference between groups before the instillation of dapiprazole(graph 2).10,12 
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Pupil diameter was measured throughout the testing and showed no 
significant difference (graph 3). 
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There were no adverse side effects noted in this study. 
Discussion-
Dapiprazole is specifically marketed as an agent to reverse mydriasis. 
Many recent studies of dapiprazole have concentrated on its effect on the 
' 
mydriasis produced by several common dilating agents, including phenylephrine, 
tropicamide, other analogs and their combinations6. These studies suggest that 
dapiprazole hastens pupillary recovery. Full recovery of pre-dilation pupil size 
occurs in approximately three hours when dapiprazole is used after instillation of 
these dilating agents, whereas without dapiprazole, recovery occurs in nearly six 
hours8. The manufacturer's literature suggests that mydriasis is the primary 
discomfort in routine dilation, but other studies show that the lack of 
accommodation is often even more annoying8,9. At any rate, dapiprazole is 
shown to have effects upon both mydriasis and accommodation recoveries when 
using either parasympatholytic2,4 (i.e. tropicamide) or sympathomimetic6 (i.e .. 
phenylephrine) drugs, even though literature indicates that dapiprazole should 
have no accommodative effects on the ciliary bodylO. There are, however, alpha 
receptors on the ciliary muscle tissue and the accommodative recovery effects 
have been shown7. 
Though tropicamide and phenylephrine tend to be the most popular drugs 
for routine dilation, often times there is a need for a drug that induces more 
cycloplegia for the purpose of a cycloplegic refraction in combination with 
dilation. Cyclopentolate is a commonly used drug for this purpose. This study 
explored dapiprazole 's effect on the reversal of cyclopentolate. Because of the 
presence of alpha receptors on the ciliary muscle tissue it was postulated that 
dapiprazolc might, indeed, have an effect. 
Despite the fact that no statistical evidence could be shown to reveal that 
dapiprazole reverses cycloplegic effects, it is worth noting that a very interesting 
and suggestive trend does exist to show that dapiprazole does appear to have some 
effect in cycloplegic reversal. Examination of the data illustrates that 
accommodation recovery is quicker in the experimental group than that of the 
control group. A significant difference is not obtained possibly due to insufficient 
numbers. The age of the test subjects could also have had a negative effect on the 
results. Another study showed that dapiprazole has limited effectiveness in the 
very young population6. Increasing the number of test subjects would aid in 
increasing the data validity obviously, but more importantly, could tum this 
suggestive trend into a statistical trend. Further studies using non-presbyopic 
middle aged subjects would also give expanded useful information. The end result 
could then lead to an affirmation of the initial proposed hypothesis that 
dapiprazole does significantly speed the time of recovery of accommodation after 
cycloplegia via cyclopentolate. 
There is no statistical significance to the change in mydriasis shown by the 
measurements of the pupil diameter, but again, increasing the number of test 
subjects and their mean age could also tum this suggestive trend into a statistical 
trend. Iris color was not controlled for in this study, but previous studies show 
that there is no statistical difference in the regain of accommodation or of 
mydriasis between darker verses lighter iris color8. Much like this study there 
was a trend that showed a faster regain of accommodation and increased miosis 
with the lighter iris. 
Though not a focus of the study, a statistically significant trend was seen 
with regards to IOP measured. Other literature suggest that dapiprazole has 
effects on lOP only after months of uselO. But through the use of the two tailed 
"t" analysis, a 21.36% difference was seen between control and experimental 
groups after the third post dapiprazole instillation period in this study. The 
results showing that the experimental group percent change decrease was, indeed, 
higher than that of the control group. This is an interesting point and sideline to 
the drug as this was not what its main purpose was for. Further evidence to this 
occurrence can be seen in another study 1 , where a 24% statistical decrease 
between experimental and control groups was seen after a short term duration 
period when utilizing the use of Rev-Eyes and tropicamide. Likewise, in the 
previously mentioned glaucoma study10, a 2-3 mmHg statistical difference in 
lOP measure was noted between the test groups over a longer test period of 6 
months. 
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